What Are Actoprotectors? The Soviet Anti-Fatigue Drug Class, Examined

Reviewed by the NootropicsJet editorial team · Published: [23.03.2018] · Last updated: [13-08-2026]

Sources: peer-reviewed literature indexed on PubMed, including one English-language review of the class, three Russian-language clinical trial reports and two rodent mechanism studies, plus the 2026 WADA Prohibited List. Every citation below carries a PMID or DOI.

Actoprotectors are a pharmacological class defined in Soviet military medicine: compounds intended to raise physical and mental work capacity under load without increasing oxygen consumption or heat production. Two compounds carry the class — bemitil and bromantane. This article explains what the category actually claims, what the human evidence supports, and where both compounds stand with regulators and anti-doping authorities. By the end you will be able to judge whether the category’s reputation is earned or inherited.

Key takeaways

• Neither compound is approved in the US or EU. Bromantane is a prescription drug in Russia under the name Ladasten. Bemitil has been certified in Ukraine as a dietary supplement. Neither holds FDA, EMA or EFSA authorization.
• Bromantane is banned in sport. It sits in class S6.A of the 2026 WADA Prohibited List as a non-specified stimulant, prohibited in competition. Non-specified status carries the standard two-year sanction with limited flexibility.
• The most-quoted human number comes from an uncontrolled study. The 90.8% responder rate for Ladasten is from an open-label multicenter study with no placebo arm (728 patients analyzed, 28 centers). In asthenia trials, placebo response is high. That figure is not an effect size.
• The mechanisms are transcriptional and demonstrated in rodents. Bromantane raises tyrosine hydroxylase expression; bemitil is described as inducing protein synthesis including gluconeogenic enzymes. Neither has been confirmed in human brain or muscle.
• Detection outlasts the drug by roughly thirty-fold. Bromantane’s plasma half-life is about 11 hours; its metabolites have been reported in urine for up to two weeks.

What are actoprotectors?

Actoprotectors are synthetic compounds developed to increase resistance to fatigue, hypoxia and heat stress during sustained physical or cognitive work. The formal definition used in the literature is a preparation that enhances the body’s stability against physical loads without increasing oxygen consumption or heat production — described in the source review as, in short, synthetic adaptogens with a significant capacity to improve physical performance (Oliynyk & Oh, 2012, Biomolecules & Therapeutics 20(5):446–456, PMID 24009833 — narrative review).

That definition is doing specific work. A classic stimulant improves output partly by increasing effort and metabolic cost: heart rate rises, thermogenesis rises, and the debt is paid afterward. The actoprotector concept proposes the opposite trade — improved output at unchanged or lower metabolic cost, achieved by shifting how cells generate and recycle energy substrate rather than by driving the catecholamine system harder.

Whether that distinction survives contact with human data is the question this article is about. It is a coherent pharmacological hypothesis. It is not a settled finding, and the class terminology itself is essentially unused outside Russian- and Ukrainian-language pharmacology.

Practical implication: treat “actoprotector” as a claim about mechanism, not as a certification of efficacy or safety. The label tells you what a compound was designed to do, not what it has been shown to do.

Are actoprotectors legal or approved?

No actoprotector is authorized by the FDA, EMA or EFSA for any use. This matters more than usual here, because the class is often discussed in English-language sources as though Soviet-era registration were equivalent to modern regulatory approval. It is not.

• Bromantane (Ladasten) is registered in Russia as a prescription-only medicine for asthenic disorders. In the United States it is unscheduled and not FDA-approved.
• Bemitil (bemethyl) was registered in the USSR in the 1980s and has been certified in Ukraine as a dietary supplement under the name Antihot (Oliynyk & Oh, 2012). That status reflects 2012 information and should be re-checked against current Ukrainian regulation.

Is bromantane banned in sport?

Yes. Bromantan appears in class S6.A of the 2026 WADA Prohibited List, the section designated non-specified stimulants, prohibited in competition.

The S6.A designation carries a practical consequence worth understanding. Specified stimulants — the S6.B group — include substances that may be taken unintentionally through widely available medical products, and an anti-doping rule violation involving them can attract a reduced sanction. Non-specified stimulants carry the standard two-year suspension with far less flexibility.

The prohibition dates to the 1996 Atlanta Olympics, where several Russian athletes tested positive. Because bromantane was not on the IOC list at the time, the cases were dismissed without consequence for the athletes; the compound was added to the prohibited list in September 1996, shortly after the Games. Positive tests were also recorded at Sydney.

Bemitil is not named on the 2026 list. That is not the same as being permitted. Category S0 covers any pharmacological substance with no current approval by any governmental regulatory health authority for human therapeutic use, and it applies at all times, in and out of competition. Whether bemitil escapes S0 depends on its regulatory classification in the relevant jurisdiction — a question for an athlete’s anti-doping officer, not for a supplement retailer. Absence from the named list is not clearance.

Practical implication: if you are tested in any federation at any level, neither compound is a defensible risk. The detection window discussed below makes “stopping in time” unworkable as a strategy.

Where the class came from

Work on this class was carried out by Professor Vladimir Vinogradov’s group at the Department of Pharmacology of the Military Medical Academy in Leningrad during the 1970s, producing bemitil as the reference compound of the category. The source review reports that this work earned Vinogradov and his team the State Prize of the USSR (Oliynyk & Oh, 2012).

The historical account that circulates in English — first use by Soviet cosmonauts, deployment in preparing the USSR national team for the 1980 Moscow Olympics, wide use across the Soviet and later Russian armed forces, and administration to responders after Chernobyl, the 1988 Armenian earthquake and the 1989 Bashkiria rail disaster — traces to this single review, which in turn cites Russian-language monographs not independently verifiable in Western databases.

None of these deployments were controlled studies. They are institutional history. They tell you that Soviet military medicine believed the compound worked. They do not tell you that it did.

One point of provenance belongs in the open. The principal English-language review of this class was co-authored by a researcher whose own published work includes studies of the dietary supplement Antihot — the Ukrainian bemitil product — in athletes, and a paper on ergogenic aids for working capacity at altitude. That is not an accusation of bad faith; the papers are cited openly in the review’s own reference list. It is a reason to want independent replication before accepting the class’s efficacy and safety framing at face value, particularly since the review’s abstract asserts “high efficiency and safety” for compounds with no modern safety surveillance.

Bemitil, bemethyl or metaprot?

The same compound appears under several names, which makes literature searches harder than they should be. Bemitil is transliterated as bemithil, bemithyl and bemethyl in English-language sources, and appears in later Russian publications as metaprot and bemactor (Oliynyk & Oh, 2012). The Ukrainian commercial name is Antihot.

Its chemical identity is 2-ethylthiobenzimidazole hydrobromide — a benzimidazole bearing a sulfur atom at the 2-position. Sources that write “2-ethylbenzimidazole,” dropping the thio, are describing a different molecule.

Actoprotectors vs adaptogens: what the distinction claims

Adaptogens — rhodiola, eleuthero, schisandra — are plant preparations proposed to raise nonspecific resistance to stressors. Actoprotectors were conceived as synthetic adaptogens with the vague part removed: single defined molecules, known structure, a specified performance endpoint under load.

	Adaptogens (e.g. Rhodiola rosea)	Actoprotectors (bemitil, bromantane)
Composition	Multi-constituent plant extract	Single synthetic molecule
Regulatory status	Widely sold as food supplements	No FDA/EMA/EFSA authorization
Human evidence	Multiple placebo-controlled trials, mixed results	Small number of trials, almost all Russian-language
Anti-doping	Generally permitted	Bromantane prohibited (S6.A)
Independent replication	Yes, in Western journals	Not identified

If you are interested in the plant side of this comparison, our analysis of rhodiola for mental fatigue covers the controlled human evidence, and natural vs synthetic nootropics covers the broader trade-off between botanical complexity and molecular precision. Both categories sit inside the wider field mapped in our guide to nootropics. Both categories sit inside the wider field of nootropics and cognitive enhancers, where the same trade-off between plant complexity and molecular precision recurs across compound classes.

How bemitil is thought to work

The proposed mechanism is metabolic rather than neurotransmitter-based. Bemitil is described as activating cellular protein synthesis, with downstream expression of enzymes involved in gluconeogenesis and mitochondrial oxidation. The practical consequence claimed is easier lactate utilization and carbohydrate resynthesis, which would support sustained work capacity (Oliynyk & Oh, 2012).

That is a genuinely interesting proposition: rather than masking fatigue, it would address one of fatigue’s substrates by helping the liver recycle lactate back into glucose. It is also, in humans, unproven. The supporting biochemistry is animal and in vitro work.

Notably, bemitil is described as having no direct free-radical scavenging activity; any antioxidant effect is attributed indirectly to induced synthesis of enzymes such as superoxide dismutase and catalase. This is an unusually specific and falsifiable claim, and it argues against the loose “antioxidant” framing the compound sometimes receives in supplement copy.

Mechanistically plausible, but not yet demonstrated in humans.

How bromantane works

Bromantane is a different molecule doing a different thing. Chemically it is N-(2-adamantyl)-N-(4-bromophenyl)amine — an adamantane cage attached to a bromoaniline, structurally unrelated to bemitil and part of the same chemical family as memantine and amantadine.

Its mechanism is transcriptional. Vakhitova and colleagues reported more than a twofold increase in tyrosine hydroxylase mRNA in rat hypothalamus approximately 1.5 to 2 hours after a single administration of ladasten — a finding from their 2004 work, subsequently referenced in a 2006 paper that identified cytosine demethylation in CpG islands of the tyrosine hydroxylase promoter as the likely mechanism behind the increased transcription (Vakhitova et al., 2006, Genetika 42(7), PMID 16915929).

Mikhaylova and colleagues mapped where these changes occur. After a single 50 mg/kg oral dose in rats, ladasten differentially regulated tyrosine hydroxylase mRNA and protein alongside dopamine and L-DOPA content across the ventral tegmental area, nucleus accumbens, hypothalamus, striatum and hippocampus (Mikhaylova et al., 2007, Neuropharmacology 53(5):601–608, doi:10.1016/j.neuropharm.2007.07.001). The rise in tyrosine hydroxylase mRNA in the ventral tegmental area tracked increased L-DOPA and dopamine content in the nucleus accumbens — the pattern a synthesis-driven mechanism should produce, with enzyme expression rising in cell bodies and product accumulating in projection targets.

Here is why that distinction matters. Amphetamine forces release of dopamine that already exists; methylphenidate blocks its reuptake. Both redistribute an existing pool. Bromantane, in rodents, appears to increase the capacity to make more — which is the pharmacological basis for the claim that it produces no crash and no tolerance. That claim is mechanistically coherent and largely untested in humans over meaningful timeframes.

Two cautions belong alongside it. First, gene-expression effects that build over days are harder to titrate and harder to stop than acute ones. Second, WADA classifies bromantane as a stimulant regardless of its kinetics — regulators categorize by effect, not by elegance of mechanism. Readers interested in other Soviet-era compounds with unusual mechanisms may find our coverage of Semax nasal spray effects a useful comparison.

How long does bromantane stay detectable?

The parent compound’s reported elimination half-life in humans is approximately 11.2 hours, with oral bioavailability near 42%. Absorption differs by sex: time to maximum plasma concentration is reported as 2.75 hours in women and 4.0 hours in men. Metabolism proceeds mainly by hydroxylation at the 6-position of the adamantane cage, and the resulting metabolites — chiefly 6β-hydroxybromantane — have been reported in urine as long as two weeks after administration, attributed to slow release from adipose tissue (Oliynyk & Oh, 2012, summarizing Russian-language pharmacokinetic work).

Converted into something practically interpretable: the detection window outlasts the plasma half-life by a factor of roughly thirty. A compound that has stopped producing any subjective effect can still produce an adverse analytical finding a fortnight later. There is no feel-based washout for this molecule.

What the human evidence actually shows

This is where most coverage of the class overstates its hand. Below is what exists, with the design labeled honestly.

Claim	Best available evidence	Tier
Bromantane reduces asthenia symptoms	Comparative clinical study with placebo in neurasthenia (Neznamov et al., 2009, Zh Nevrol Psikhiatr Im S S Korsakova 109(5):20–26, PMID 19491814)	3 — Preliminary
Bromantane responder rates of 76–91%	Open-label, uncontrolled multicenter study, no placebo arm (Voznesenskaia et al., 2010, PMID 21322821)	3 — Preliminary
Bromantane combines stimulant and anxiolytic effects	Clinical trial (Siuniakov et al., 2006, Eksp Klin Farmakol 69(4):10–15, PMID 16995430)	3 — Preliminary
Bemitil improves work capacity under hypoxia or heat	Soviet-era studies cited within a review; primary reports not independently verifiable	3, weakly held
Bemitil induces gluconeogenic and antioxidant enzyme synthesis	Animal and in vitro work	4 — Mechanistic
Bromantane upregulates tyrosine hydroxylase expression	Rodent studies	4 — Mechanistic

The number worth dwelling on is the one everyone repeats. The multicenter Ladasten study ran across 28 Russian centers and analyzed data on 728 patients with psychoautonomic syndrome, all with asthenic disorders, treated at 50–100 mg daily for 28 days. Responder rates were 76.0% on the CGI-S and 90.8% on the CGI-I; the antiasthenic effect appeared by day 3 and persisted for a month after withdrawal. Adverse effects occurred in 3% of patients, therapy was discontinued in 0.8%, and no serious adverse effects were reported (Voznesenskaia, Fokina & Iakhno, 2010, Zh Nevrol Psikhiatr Im S S Korsakova 110(5):17–26, PMID 21322821 — open-label multicenter study).

Read the design, not the percentage. There was no placebo arm. In fatigue and asthenia trials, placebo response rates are routinely high, because the primary outcomes are subjective and the conditions fluctuate. A 90.8% improvement rate in an uncontrolled study tells you that patients and clinicians reported improvement; it does not tell you how much of that improvement the drug caused. Sources that present this figure as evidence of near-universal efficacy are misreading a study design, not reporting a result.

The doses above are trial parameters reported for context. They are not guidance, and this article does not provide a dosing protocol.

The placebo-comparative trial is the more informative study, and it is also the one nobody quotes, because its abstract reports direction without magnitude. That asymmetry — the weaker study supplying the memorable number, the stronger study supplying an unquantified one — is the single most important thing to understand about this evidence base.

Do actoprotectors improve performance under hypoxia?

The hypoxia claim is the class’s founding proposition and its least verifiable. Bemitil’s reported use in Soviet air, missile and naval forces, and at altitude, comes from Russian-language sources summarized in review form. No controlled trial published in a Western journal has tested either compound under hypoxic conditions. The mechanism — improved lactate reutilization and mitochondrial oxidation — is plausible. The human outcome is unconfirmed by any independent group.

Safety, side effects and interactions

There is no modern safety dataset for either compound in healthy Western populations, and no post-marketing surveillance system that would detect rare harms.

What the literature reports: in the open-label Ladasten study, adverse effects occurred in 3% of patients and 0.8% discontinued, with no serious adverse effects recorded (Voznesenskaia et al., 2010). Reported effects for bemethyl in secondary sources include headache, dizziness, sleep disturbance and reduced appetite; these have not been characterized in a dedicated safety trial. Both datasets come from studies not designed primarily to assess safety.

Interactions to consider by drug class, not by treatment plan:

• Dopaminergic and stimulant medications, including MAO inhibitors — bromantane’s proposed mechanism increases dopamine synthesis capacity; additive dopaminergic effects are a theoretical concern.
• Drugs with narrow therapeutic indices cleared hepatically — bromantane undergoes hepatic metabolism, and its interaction profile with other hepatically cleared drugs has not been characterized in humans. Treat the interaction potential as unknown rather than absent.
• Anything with sedative or anxiolytic action — the anxiolytic component has not been characterized for interaction potential.

Who should not use these compounds: anyone pregnant or breastfeeding, anyone under 18, anyone with a psychiatric or cardiovascular diagnosis, anyone taking prescription medication, and any athlete subject to anti-doping testing. There is no human data supporting use in any of these groups, and for the last there is a clear prohibition. For anything specific to your own health or medication, speak to a qualified healthcare professional rather than to a forum.

What we still don’t know

• Whether the transcriptional mechanism observed in rodents occurs in the human brain at all.
• Whether the “no tolerance, no withdrawal” claim holds beyond 28 days, the longest well-described trial duration.
• What the effect size is in the placebo-comparative trial.
• Whether bemitil does anything measurable in healthy, well-rested people, as opposed to depleted or asthenic ones.
• Whether any of this replicates outside the research tradition that produced it. Fifty years after the class was named, that remains the load-bearing unanswered question.

The bottom line

Actoprotectors are a real pharmacological idea with a thin, geographically isolated evidence base. The concept — improving work capacity by changing energy metabolism and synthesis capacity rather than by acute stimulation — is well specified and worth taking seriously as a hypothesis. The supporting human data is small, mostly uncontrolled, published in one language, and unreplicated.

This category is not for you if you compete in tested sport at any level; if you want a compound with a modern safety profile; if you take prescription medication; or if you require evidence that has survived independent scrutiny. That last exclusion covers most readers, and saying so is more useful than pretending otherwise.

If your actual problem is sustained mental energy rather than pharmacological curiosity, the evidence for caffeine-free approaches to clean focus is considerably better characterized than anything in this article. That is where we would send a reader who came here looking for a solution rather than an explanation.

Frequently asked questions

What are actoprotectors in simple terms? Actoprotectors are synthetic compounds designed to increase physical and mental work capacity under stress without raising oxygen consumption or body heat. The class was defined in Soviet military pharmacology in the 1970s. Its two main representatives are bemitil, a benzimidazole, and bromantane, an adamantane derivative. Neither is approved in the US or EU.

Are actoprotectors the same as adaptogens? They were conceived as synthetic adaptogens — single defined molecules aiming at the same nonspecific stress-resistance effect claimed for plants like rhodiola. The practical differences are large: adaptogens are widely sold food supplements with multiple placebo-controlled trials in Western journals, while actoprotectors are unapproved pharmaceuticals whose human evidence is almost entirely Russian-language and unreplicated.

Is bromantane banned in sport? Yes. Bromantan appears in class S6.A of the 2026 WADA Prohibited List as a non-specified stimulant, prohibited in competition. Non-specified status carries the standard two-year sanction. The prohibition followed positive tests at the 1996 Atlanta Olympics, after which the compound was added to the IOC list. Bemitil is not named on the list, but that is not clearance — category S0 covers unapproved pharmacological substances at all times.

How long does bromantane stay detectable? Longer than it stays active. The parent compound’s reported human half-life is roughly 11 hours, but its hydroxylated metabolites have been reported in urine for up to two weeks after administration, attributed to slow release from adipose tissue. There is no reliable way to time a washout by subjective effect.

Does bemethyl work like a stimulant? Not according to its proposed mechanism. Bemitil is described as inducing protein synthesis — including gluconeogenic and antioxidant enzymes — which would improve lactate recycling and substrate availability rather than driving acute arousal. That mechanism rests on animal and biochemical work. It has not been demonstrated in humans.

Is there good human evidence for actoprotectors? Not by modern standards. The strongest study is a placebo-comparative trial of bromantane in neurasthenia whose abstract reports superiority over placebo without an effect size. The widely quoted 90.8% responder figure comes from an uncontrolled open-label study with no placebo arm, and cannot be read as an effect of the drug.

This article is for educational purposes and describes pharmacology and regulatory status. It is not medical advice, does not recommend use of any compound described, and does not replace consultation with a qualified healthcare professional. The compounds discussed are not approved by the FDA, EMA or EFSA, and bromantane is prohibited in competitive sport.

REFERENCES

1. Oliynyk S, Oh S. The pharmacology of actoprotectors: practical application for improvement of mental and physical performance. Biomol Ther (Seoul). 2012;20(5):446–456. doi:10.4062/biomolther.2012.20.5.446. PMID 24009833. PMC3762282.
2. Voznesenskaia TG, Fokina NM, Iakhno NN. Treatment of asthenic disorders in patients with psychoautonomic syndrome: results of a multicenter study on efficacy and safety of ladasten. Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110(5):17–26. PMID 21322821. (Russian)
3. Neznamov GG, Siuniakov SA, Teleshova SE, et al. Ladasten, the new drug with psychostimulant and anxiolytic actions in treatment of neurasthenia (results of the comparative clinical study with placebo). Zh Nevrol Psikhiatr Im S S Korsakova. 2009;109(5):20–26. PMID 19491814. (Russian)
4. Siuniakov SA, Grishin SA, Teleshova ES, Neznamov GG, Seredenin SB. Eksp Klin Farmakol. 2006;69(4):10–15. PMID 16995430. (Russian)
5. Vakhitova IuV, Sadovnikov SV, Iamidanov RS, Seredenin SB. Cytosine demethylation in the tyrosine hydroxylase gene promoter in the hypothalamus cells of the rat brain under the action of an aminoadamantane derivative Ladasten. Genetika. 2006;42(7). PMID 16915929. (Russian)
6. Mikhaylova M, Vakhitova JV, Yamidanov RS, Salimgareeva MKh, Seredenin SB, Behnisch T. The effects of ladasten on dopaminergic neurotransmission and hippocampal synaptic plasticity in rats. Neuropharmacology. 2007;53(5):601–608. doi:10.1016/j.neuropharm.2007.07.001.
7. World Anti-Doping Agency. Prohibited List 2026, class S6.A (non-specified stimulants).